Key Milestones

2016

  • Humanetics is awarded a grant from the National Space Biology Research Institute to study BIO 300 for space like radiation protection
  • Humanetics is awarded a SBIR grant from the National Institute of Allergy and Infection Disease to study BIO 300 for mitigation of lung injury as a delayed effect of acute radiation exposure

2015

  • Humanetics begins enrollment in Phase I/II clinical trial in non-small cell lung cancer
  • FDA clears IND 119322 for adjunctive treatment of non-small cell lung cancer with BIO 300

2014

  • Humanetics is awarded a new STTR grant from the National Cancer Institute (NCI) to study the protective effects of BIO 300 in a preclinical model of prostate cancer
  • Humanetics receives approval from NCI to enter Phase II of its Fast Track Contract to test the protective effects of BIO 300 on non-small cell lung cancer patient

2013

  • U.S. patent 8,551,530 issues for a nanoparticle formulation of BIO 300 allowing oral adminstration

2012

  • Awarded a $1.7 million Fast Track Contract from the National Cancer Institute to study BIO 300 as a treatment for patients undergoing chemoradiation treatment for non-small cell lung cance

2011

  • Receives a $3.5 million dollar contract from the Biomedical Advances Research and Development Authority to pursue development of BIO 300 as a post-irradiation treatment to prevent pneumonitis and fibrosis of the lung
  • Receives $333,779 from the Internal Revenue Service under the Qualified Therapeutics Discovery Project for funding of Alzheimer’s and Post Traumatic Stress Disorders programs

2010

  • Obtains exclusive rights to develop BIO 700 and BIO 800 for the treatment of Acute Radiation Syndrome and Delayed Effects of Radiation Injury

2009

  • Receives $600,000 NIAID Grant to study BIO 600 for Acute Radiation Syndrome

2008

  • Successfully completes Phase I Safety and Pharmacokinetic trial for BIO 300

2007

  • Receives second appropriation from the Department of Defense to fund medical radiation countermeasure programs
  • Begins Phase I and II trials for BIO 300
  • Receives first-ever Orphan Drug designation for a medical radiation countermeasure
  • Receives third appropriation from the Department of Defense to fund medical radiation countermeasure programs

2006

  • Obtains clearance from FDA to begin clinical studies for BIO 300 under an Investigational New Drug (IND) application

2005

  • Signs Unique Master Research and Development Cooperative Agreement (CRADA) with AFRRI
  • Obtains Exclusive Worldwide License for BIO 300 Compound for ARS Countermeasure

2003

  • Begins Collaboration with Armed Forces Radiobiology Research Institute (AFRRI) to discover and develop medical radiation countermeasures